Oncoinvent (ONCIN) EGM 2025 summary

Opening remarks and agenda

• Chair welcomed shareholders and introduced key participants, including the CEO and legal counsel.

• Meeting was held digitally with all shareholders participating online.

• Agenda included election of meeting chair, co-signer of minutes, approval of notice and agenda, and resolutions on share capital changes.

Specific resolutions to be voted on

• Election of Jan Brudvik as chairperson of the meeting, approved unanimously.

• Election of Renate Birkeli to co-sign the minutes, approved unanimously.

• Approval of the notice and agenda, with 100% in favor.

• Approval of the audited interim balance sheet as of 31 October 2025, with 99.99% in favor.

• Reduction of nominal share value from NOK 1 to NOK 0.5, subject to completion of the rights issue, approved with 99.99% in favor.

• Increase in share capital in connection with the rights issue, approved with 99.99% in favor.

Overview of voting outcomes

• 52,792,437 shares represented, constituting 33.70% of share capital.

• All proposals received overwhelming approval, with most items passing with 99.99% or 100% of votes.